Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: A population-based, case-control study

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 767-778

  Koning, Marije ^a   Ailabouni, Ramez ^b   Gearry, Richard B ^a,b   Frampton, Christopher M A ^b   Barclay, Murray L ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Case control study; Complementary and alternative medicine; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

VITAMIN;

ADULT; AGED; ALTERNATIVE MEDICINE; ASTHMA; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; EDUCATIONAL STATUS; ENTERITIS; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIAL CLASS; ULCERATIVE COLITIS; VEGETARIAN;

ADMINISTRATION, ORAL; ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COMPLEMENTARY THERAPIES; CROHN DISEASE; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; ODDS RATIO; PREVALENCE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84876367445     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31827f27c8     Document Type: Review

References (52)

1. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274-1282.
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;12:6102-6108.
3. Jussila A, Virta LJ, Kautiainen H, et al. Increasing incidence of inflammatory bowel diseases between 2000 and 2007: A nationwide register study in Finland. Inflamm Bowel Dis. 2012;18:555-561.
4. NCCAM. CAM Basics: What is Complementary and Alternative Medicine? Available at: http://nccamnihgov/health/whatiscam. Updated July 2011. Accessed January 9, 2012.
5. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998;280:1569-1575.
6. Metcalfe A, Williams J, McChesney J, et al. Use of complementary and alternative medicine by those with a chronic disease and the general population- results of a national population based survey. BMC Complement Altern Med. 2010;10:58.
7. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008;10:1-23.
8. MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust. 2006;184:27-31.
9. Xue CC, Zhang AL, Lin V, et al. Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med. 2007;13:643-650.
10. Hilsden RJ, Verhoef MJ, Rasmussen H, et al. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:655-662.
11. Rawsthorne P, Clara I, Graff LA, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut. 2011;61:521-527.
12. Bensoussan M, Jovenin N, Garcia B, et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol. 2006;30:14-23.
13. Hilsden RJ, Meddings JB, Verhoef MJ. Complementary and alternative medicine use by patients with inflammatory bowel disease: an Internet survey. Can J Gastroenterol. 1999;13:327-332.
14. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005;11:287-295.
15. Joos S, Rosemann T, Szecsenyi J, et al. Use of complementary and alternative medicine in Germany-a survey of patients with inflammatory bowel disease. BMC Complement Altern Med. 2006;6:19.
16. Niggemann B, Gruber C. Side-effects of complementary and alternative medicine. Allergy. 2003;58:707-716.
17. Lakatos PL, Czegledi Z, David G, et al. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis. 2010;4:283-290.
18. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis. 2002;8:174-179.
19. Li FX, Verhoef MJ, Best A, et al. Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol. 2005;19:567-573.
20. Weizman AV, Ahn E, Thanabalan R, et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:342-349.
21. Sirois FM. Provider-based complementary and alternative medicine use among three chronic illness groups: associations with psychosocial factors and concurrent use of conventional health-care services. Complement Ther Med. 2008;16:73-80.
22. Hilsden RJ, Verhoef MJ, Best A, et al. Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey. Am J Gastroenterol. 2003;98:1563-1568.
23. Gearry RB, Richardson A, Frampton CM, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis. 2006;12:936-943.
24. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
25. Elley WB, Irving JC. The Elley-Irving socio-economic index, 1981 Census review. NZ J Educ Stud. 1985;20:115-128.
26. Galbraith CJG, Davis P, Coope P. New Zealand Socio-Economic Index 1996: User's Guide. Wellington, New Zealand: Statistics New Zealand; 2003.
27. Davis P, McLeod K, Ransom M, et al. The New Zealand Socio-Economic Index of occupational status (NZSEI). Wellington, New Zealand: Statistics New Zealand; 1997.
28. Davis P, McLeod K, Ransom M, et al. The New Zealand Socioeconomic Index: developing and validating an occupationally-derived indicator of socio-economic status. Aust N Z J Public Health. 1999;23:27-33.
29. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
30. Hedin CR, Mullard M, Sharratt E, et al. Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2010;16:2099-2108.
31. Kong SC, Hurlstone DP, Pocock CY, et al. The Incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol. 2005;39:138-141.
32. Cotton S, Humenay Roberts Y, Tsevat J, et al. Mind-body complementary alternative medicine use and quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:501-506.
33. Gerasimidis K, McGrogan P, Hassan K, et al. Dietary modifications, nutritional supplements and alternative medicine in paediatric patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:155-165.
34. Moser G, Tillinger W, Sachs G, et al. Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. J Psychosom Res. 1996;40:503-509.
35. Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use? Am J Gastroenterol. 2004;99:889-893.
36. Ausfeld-Hafter B, Hoffmann S, Seibold F, et al. [Status of alternative medicine in Crohn disease and ulcerative colitis patents: a questionnaire survey]. Forsch Komplementarmed Klass Naturheilkd. 2005;12:134-138.
37. Langhorst J, Anthonisen IB, Steder-Neukamm U, et al. Patterns of complementary and alternative medicine (CAM) use in patients with inflammatory bowel disease: perceived stress is a potential indicator for CAM use. Complement Ther Med. 2007;15:30-37.
38. Barnes PM, Powell-Griner E, McFann K, et al. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;343:1-19.
39. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet. 1996;347:569-573.
40. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med. 2002;35:166-173.
41. Rossler W, Lauber C, Angst J, et al. The use of complementary and alternative medicine in the general population: results from a longitudinal community study. Psychol Med. 2007;37:73-84.
42. Ernst E, White A. The BBC survey of complementary medicine use in the UK. Complement Ther Med. 2000;8:32-36.
43. Hoek AC, Luning PA, Stafleu A, et al. Food-related lifestyle and health attitudes of Dutch vegetarians, non-vegetarian consumers of meat substitutes, and meat consumers. Appetite. 2004;42:265-272.
44. Thomas K, Coleman P. Use of complementary or alternative medicine in a general population in Great Britain. Results from the National Omnibus survey. J Public Health (Oxf). 2004;26:152-157.
45. Ng TP, Wong ML, Hong CY, et al. The use of complementary and alternative medicine by asthma patients. QJM. 2003;96:747-754.
46. Marino LA, Shen J. Characteristics of complementary and alternative medicine use among adults with current asthma, 2006. J Asthma. 2010;47:521-525.
47. Sibbritt D, Adams J, Lui CW. A longitudinal analysis of complementary and alternative medicine use by a representative cohort of young Australian women with asthma, 1996-2006. J Asthma. 2011;48:380-386.
48. Hilsden RJ, Scott CM, Verhoef MJ. Complementary medicine use by patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:697-701.
49. Langmead L, Dawson C, Hawkins C, et al. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther. 2002;16:197-205.
50. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, doubleblind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:739-747.
51. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis. 2008;14:1585-1596.
52. Gearry RB, Richardson AK, Frampton CM, et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25:325-333.